Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Viral Hepatitis
All things being equal, what patient factors are you looking at in the selection of TAF or TDF in the management of hepatitis B?
Answer from: at Academic Institution
If renal function is normal and bone density is not a concern, TDF is much less expensive and has excellent long-term safety.
Sign In
or
Register
to read more
28154
Related Questions
What role is there for the use of ursodiol in relapsing hepatitis A for management of liver enzyme abnormalities and patient symptoms?
What role is there for the assessment of hepatitis B virus genotype as it pertains to pharmacologic therapy and HCC screening?
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
Pending final results, but in what scenario would you select bepirovirsen as opposed to established therapy for hepatitis B patients (ex: TAF or TDF)?
In what scenario do you screen patients with hepatitis B for hepatitis D co-infection?
In what scenarios do you defer treatment of a patient's hepatitis C if they are undergoing liver transplant evaluation?
When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?
Should an individual who received the purified protein Hepatitis B vaccine in 1985 receive a booster or have antibody titers checked?
What kind of monitoring do you choose in patients at risk for reactivation of hepatitis B who are on immunosuppression?
In patients with hepatitis B and co-infection with hepatitis D, given their increased risk of development of HCC, how do you approach screening for this?